Giamarellos-Bourboulis EJ - Search Results

1

Rifaximin: The Revolutionary Antibiotic Approach for Irritable Bowel Syndrome.

Triantafyllou K, Sioulas AD, Giamarellos-Bourboulis EJ. Triantafyllou K, et al. Mini Rev Med Chem. 2015;16(3):186-92. doi: 10.2174/1389557515666150722105340. Mini Rev Med Chem. 2015. PMID: 26202193 Review.

2

Carrier systems for the local delivery of antibiotics in bone infections.

Kanellakopoulou K, Giamarellos-Bourboulis EJ. Kanellakopoulou K, et al. Drugs. 2000 Jun;59(6):1223-32. doi: 10.2165/00003495-200059060-00003. Drugs. 2000. PMID: 10882159 Review.

3

Treatment of experimental osteomyelitis caused by methicillin-resistant Staphylococcus aureus with a biodegradable system of lactic acid polymer releasing pefloxacin.

Kanellakopoulou K, Galanakis N, Giamarellos-Bourboulis EJ, Rifiotis C, Papakostas K, Andreopoulos A, Dounis E, Karagianakos P, Giamarellou H. Kanellakopoulou K, et al. J Antimicrob Chemother. 2000 Aug;46(2):311-4. doi: 10.1093/jac/46.2.311. J Antimicrob Chemother. 2000. PMID: 10933660

4

Bacterial translocation following intrabdominal surgery. Any influence of antimicrobial prophylaxis?

Koratzanis G, Giamarellos-Bourboulis EJ, Papalambros E, Giamarellou H. Koratzanis G, et al. Int J Antimicrob Agents. 2002 Dec;20(6):457-60. doi: 10.1016/s0924-8579(02)00237-6. Int J Antimicrob Agents. 2002. PMID: 12458141

5

Antimicrobial-induced endotoxaemia in patients with sepsis in the field of acute pyelonephritis.

Giamarellos-Bourboulis EJ, Perdios J, Gargalianos P, Kosmidis J, Giamarellou H. Giamarellos-Bourboulis EJ, et al. J Postgrad Med. 2003 Apr-Jun;49(2):118-22. J Postgrad Med. 2003. PMID: 12867685 Free article. Clinical Trial.

6

A bioresorbable calcium phosphate delivery system with teicoplanin for treating MRSA osteomyelitis.

Lazarettos J, Efstathopoulos N, Papagelopoulos PJ, Savvidou OD, Kanellakopoulou K, Giamarellou H, Giamarellos-Bourboulis EJ, Nikolaou V, Kapranou A, Papalois A, Papachristou G. Lazarettos J, et al. Clin Orthop Relat Res. 2004 Jun;(423):253-8. doi: 10.1097/01.blo.0000127422.06956.35. Clin Orthop Relat Res. 2004. PMID: 15232458

7

Experimental sepsis using Pseudomonas aeruginosa: the significance of multi-drug resistance.

Giamarellos-Bourboulis EJ, Koussoulas V, Panagou C, Adamis T, Baziaka F, Skiadas I, Perrea D, Dionyssiou-Asteriou A, Giamarellou H. Giamarellos-Bourboulis EJ, et al. Int J Antimicrob Agents. 2004 Oct;24(4):357-61. doi: 10.1016/j.ijantimicag.2004.03.025. Int J Antimicrob Agents. 2004. PMID: 15380261

8

Clarithromycin co-administered with amikacin attenuates systemic inflammation in experimental sepsis with Escherichia coli.

Giamarellos-Bourboulis EJ, Baziaka F, Antonopoulou A, Koutoukas P, Kousoulas V, Sabracos L, Panagou C, Perrea D, Giamarellou H. Giamarellos-Bourboulis EJ, et al. Int J Antimicrob Agents. 2005 Feb;25(2):168-72. doi: 10.1016/j.ijantimicag.2004.08.018. Int J Antimicrob Agents. 2005. PMID: 15664488

9

Clarithromycin is an effective immunomodulator when administered late in experimental pyelonephritis by multidrug-resistant Pseudomonas aeruginosa.

Giamarellos-Bourboulis EJ, Antonopoulou A, Raftogiannis M, Koutoukas P, Tsaganos T, Tziortzioti V, Panagou C, Adamis T, Giamarellou H. Giamarellos-Bourboulis EJ, et al. BMC Infect Dis. 2006 Feb 21;6:31. doi: 10.1186/1471-2334-6-31. BMC Infect Dis. 2006. PMID: 16504031 Free PMC article.

10

Clarithromycin is an effective immunomodulator in experimental pyelonephritis caused by pan-resistant Klebsiella pneumoniae.

Giamarellos-Bourboulis EJ, Tziortzioti V, Koutoukas P, Baziaka F, Raftogiannis M, Antonopoulou A, Adamis T, Sabracos L, Giamarellou H. Giamarellos-Bourboulis EJ, et al. J Antimicrob Chemother. 2006 May;57(5):937-44. doi: 10.1093/jac/dkl084. Epub 2006 Mar 20. J Antimicrob Chemother. 2006. PMID: 16549515

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results